Olema Pharmaceuticals (OLMA) Depreciation & Amortization (CF) (2020 - 2026)
Olema Pharmaceuticals (OLMA) posted quarterly Depreciation & Amortization (CF) of $119000.0 for Q1 2026, down 7.03% year-over-year from $128000.0 in Q1 2025, and down 36.36% quarter-over-quarter from $187000.0 in Q4 2025.
Powered by 
Analysis
Olema Pharmaceuticals (OLMA) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has reported Depreciation & Amortization (CF) for 7 consecutive years, with $119000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 7.03% year-over-year to $119000.0; the TTM figure through Mar 2026 stood at $481000.0 (up 11.09% YoY), while the FY2025 annual figure was $490000.0, up 24.68% from the prior year.
- Depreciation & Amortization (CF) slipped to $119000.0 in Q1 2026 per OLMA's latest filing, from $187000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $187000.0 in Q4 2025 and bottomed at $43000.0 in Q3 2025.
- Historically, Depreciation & Amortization (CF) has averaged $102117.6 across 5 years, with a median of $95000.0 in 2024.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) soared 833.33% — and 2025, when it sank 54.74%.
- Olema Pharmaceuticals' Depreciation & Amortization (CF) stood at $97000.0 in 2022, then dropped by 9.28% to $88000.0 in 2023, then soared by 31.82% to $116000.0 in 2024, then surged by 61.21% to $187000.0 in 2025, then sank by 36.36% to $119000.0 in 2026.
- Business Quant data shows OLMA's Depreciation & Amortization (CF) at $119000.0 in Q1 2026, $187000.0 in Q4 2025, and $43000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Olema Pharmaceuticals | 1.13 Bn | 1.13 Bn | - | 102,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 102,000.00 |
| Mar 31, 2026 | 119,000.00 |
| Dec 31, 2025 | 187,000.00 |
| Sep 30, 2025 | 43,000.00 |
| Jun 30, 2025 | 132,000.00 |
| Mar 31, 2025 | 128,000.00 |
| Dec 31, 2024 | 116,000.00 |
| Sep 30, 2024 | 95,000.00 |
| Jun 30, 2024 | 94,000.00 |
| Mar 31, 2024 | 88,000.00 |
| Dec 31, 2023 | 88,000.00 |
| Sep 30, 2023 | 90,000.00 |
| Jun 30, 2023 | 99,000.00 |
| Mar 31, 2023 | 100,000.00 |
| Dec 31, 2022 | 97,000.00 |
| Sep 30, 2022 | 91,000.00 |
| Jun 30, 2022 | 85,000.00 |
| Mar 31, 2022 | 84,000.00 |
| Dec 31, 2021 | 73,000.00 |
| Sep 30, 2021 | 50,000.00 |